Cell line · CVCL_2169
Papers34
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 34
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Vitamin D decreases tumor cell growth and invasiveness in primary malignant bone tumors in vitro. | J Bone Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 40376089 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. | Cancer Gene Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. | Cell Rep | 2022 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma. | Transl Oncol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Systematic multi-omics profiling of Ewing sarcoma cell lines. | 2021 | Cellosaurus cites it | DOI | ||
| ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. | Cell Rep | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. | Cancer Res | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. | Mol Ther | 2019 | Cellosaurus cites it | PubMed | |
| T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. | Oncotarget | 2018 | Cellosaurus cites it | PubMed | |
| Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 | Cellosaurus cites it | PubMed | |
| CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients. | Eur J Cancer | 2015 | Cellosaurus cites it | PubMed | |
| Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. | Mol Cancer Ther | 2015 | Cellosaurus cites it | PubMed | |
| A resource for cell line authentication, annotation and quality control. | Nature | 2015 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2169/papers